Denied Stelara? You Still Have Options.
Stelara (ustekinumab) is prescribed for Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis — and it's one of the specialty medications most commonly flagged for prior authorization denials. Insurers across all of these conditions typically require step therapy, meaning you may have to try and fail other biologics (like TNF inhibitors) before they'll approve Stelara. Formulary restrictions and the medication's cost are also factors that lead to denials even when your doctor considers it the right choice.
Option 1: Appeal Your Denial
If you've already tried other biologics and they didn't work or caused side effects, that documentation is your strongest appeal argument. Your doctor's letter of medical necessity — clearly explaining your treatment history and why Stelara is the appropriate next step — gives you a real shot at overturning the denial. Ellen can help you draft your appeal letter.
Option 2: Explore Clinical Trials
Ustekinumab and related IL-12/23 inhibitors are active areas of research across inflammatory bowel disease and dermatology. Clinical trials may study Stelara directly, biosimilars in development, or next-generation therapies in the same class. Participants in approved trials often receive the study medication at no cost. Search ClinicalTrials.gov for "ustekinumab," "Crohn's disease," or your specific condition.
Option 3: Patient Assistance Programs
Janssen, Stelara's manufacturer, offers the Janssen CarePath program, which provides financial assistance and access support for eligible individuals. Disease-specific organizations like the Crohn's and Colitis Foundation (crohnscolitisfoundation.org) and the National Psoriasis Foundation (psoriasis.org) also offer financial navigation support.
For a complete guide to Stelara financial assistance — including copay cards, free drug programs, and independent foundations — see our financial assistance page for Stelara.
Ellen can help you figure out your next step. Start with Ellen →
Frequently Asked Questions
Why was Stelara denied?
Stelara is most often denied because of step therapy requirements — your insurer wants to see that you've tried less expensive biologics (usually TNF inhibitors like Humira or Remicade) before approving a more targeted therapy. It can also be denied due to missing prior authorization or because the diagnosis submitted doesn't perfectly align with the plan's covered indications. Reading your denial letter carefully tells you exactly which argument your appeal should address.
Can I get Stelara through a clinical trial?
Some clinical trials study ustekinumab directly, and others study biosimilars or next-generation therapies in the same class. If a trial is studying Stelara or something closely related for your condition, qualified participants generally receive the medication at no charge. Trial eligibility depends on your specific diagnosis, health history, and what studies are enrolling near you. Talk to your doctor about whether this is a realistic path for you.
How long does a Stelara appeal take?
Standard internal appeals are typically decided within 30 days. Urgent appeals must be resolved within 72 hours when your doctor certifies medical urgency. After an internal denial, you can request an independent external review, which generally takes up to 45 days. Your plan's denial letter will include the specific deadlines. Talk to your doctor before making any decisions about your treatment.